Hyperfine Inc

Hyperfine Inc (HYPR) Stock Analysis

$0.685

-0.059 (-8.65%)At close

Loading chart…
High
0.755
Open
0.751
VWAP
0.70
Volume
826.77K
Mkt Cap
68.77M
Low
0.670
Amount
581.58K
EV/EBITDA, TTM
-0.87

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.

AI analysis of Hyperfine Inc (HYPR)

Hold

Hyperfine Inc (HYPR) is currently priced at $0.7227, which is significantly below its 52-week high of $1.94, indicating potential upside. However, the RSI of 36.757 suggests the stock is currently oversold, and the company has a gross margin of 50.72%, indicating it can maintain profitability despite challenges. The main risk is the negative net income, which was -$9,298,000 in Q2 2026, showing ongoing financial struggles. Given these factors, while there is potential for recovery, the current financial instability suggests a hold rather than a buy at this time.

Valuation Metrics

The current forward P/E ratio for Hyperfine Inc (HYPR) is 0.00, compared to its 5-year average forward P/E of -2.17.

Forward P/E

Strongly Overvalued
5Y Average P/E
-2.17
Current P/E
0.00
Overvalued
-1.13
Undervalued
-3.20

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.86
Current EV/EBITDA
-0.87
Overvalued
0.95
Undervalued
-2.67

Forward P/S

Fair
5Y Average P/S
7.65
Current P/S
2.96
Overvalued
15.80
Undervalued
-0.49

Whales holding HYPR

A

Alphabet Inc.

+ HoldingHYPR

+0.00%

3M Return

Events Timeline

2026-10-22 (ET)

08:30:00

Hyperfine Receives CE Mark and UKCA Approval for Optive AI Software

2026-10-08 (ET)

12:30:00

Major Averages Decline as Oil Prices Surge

08:00:00

Management Expects 2026 Revenue of $20M-$22M

08:00:00

Hyperfine Expects Q3 2026 Net Cash Burn of Approximately $5.6M

2026-09-28 (ET)

08:30:00

Hyperfine Appoints Roots Pharmaceutical as Exclusive Distributor for Kuwait and UAE

News

HYPR FAQ — answered by Alphio AI

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Hyperfine Inc (HYPR) is currently priced at $0.7227, which is significantly below its 52-week high of $1.94, indicating potential upside. However, the RSI of 36.757 suggests the stock is currently oversold, and the company has a gross margin of 50.72%, indicating it can maintain profitability despite challenges. The main risk is the negative net income, which was -$9,298,000 in Q2 2026, showing ongoing financial struggles. Given these factors, while there is potential for recovery, the current financial instability suggests a hold rather than a buy at this time.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading